APA (7th ed.) Citation

Garralda, E., Hoef, M. v., Ochsenreither, S., Gianni, L., Lorusso, D., Fiedler, W., . . . Kebenko, M. (2018). 1510TiPThe GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy292.131

Chicago Style (17th ed.) Citation

Garralda, E., et al. "1510TiPThe GATTO Study: A Phase I of the Anti-EGFR Tomuzotuximab (TO) in Combination with the Anti-MUC1 Gatipotuzumab (GAT) in Patients with EGFR Positive Solid Tumors." Annals of Oncology 29 (2018): N.PAG. https://doi.org/10.1093/annonc/mdy292.131.

MLA (9th ed.) Citation

Garralda, E., et al. "1510TiPThe GATTO Study: A Phase I of the Anti-EGFR Tomuzotuximab (TO) in Combination with the Anti-MUC1 Gatipotuzumab (GAT) in Patients with EGFR Positive Solid Tumors." Annals of Oncology, vol. 29, 2018, p. N.PAG, https://doi.org/10.1093/annonc/mdy292.131.